Preoperative iron status is a prognosis factor for stage II and III colorectal cancer.

Colorectal cancer Fusobacterium nucleatum Iron Prognosis Transferrin saturation

Journal

International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295

Informations de publication

Date de publication:
Nov 2021
Historique:
received: 02 02 2021
accepted: 19 07 2021
pubmed: 25 7 2021
medline: 21 10 2021
entrez: 24 7 2021
Statut: ppublish

Résumé

Iron deficiency anemia is represented in colorectal cancer (CRC) patients. Iron surplus load to increase non-transferrin bound iron (NTBI), and NTBI promotes cancer progression and influences microbiota. This study investigated whether preoperative serum iron status was associated with prognosis after CRC resection. We evaluated preoperative iron and transferrin saturation (TSAT), which was calculated as iron divided by total iron-binding capacity, in 327 patients who underwent surgery for Stage II-III CRC. Fe < 60 μg/dl and TSAT > 40% were defined as low and high iron, respectively. The associations between iron status and overall survival (OS) were evaluated in univariate and multivariate Cox proportional hazards analysis. Of the 327 patients, 179 (54.7%), 124 (37.9%) and 24 (7.3%) had low, normal and high iron, respectively. In univariate analysis, low iron was associated with shorter OS (hazard ratio [HR] 2.821, 95% confidence interval [CI] 1.451-5.485, P = 0.002). High iron was also associated with shorter OS (HR 3.396, 95% CI 1.359-8.489, P = 0.009). In multivariate analysis, high age (P = 0.002), depth of invasion pT4 (P = 0.012), lymph-node metastasis presence (P = 0.035), low albumin (P = 0.011), low iron (HR 2.282, 95% CI 1.163-4.478, P = 0.016) and high iron (HR 3.757, 95% CI 1.486-9.494 P = 0.005) were independently associated with shorter OS. High iron was associated with the amount of intratumoral Fusobacterium nucleatum compared with normal iron. Both low and high preoperative iron in Stage II-III CRC patients were associated with unfavorable OS in univariate and multivariate analyses.

Sections du résumé

BACKGROUND BACKGROUND
Iron deficiency anemia is represented in colorectal cancer (CRC) patients. Iron surplus load to increase non-transferrin bound iron (NTBI), and NTBI promotes cancer progression and influences microbiota. This study investigated whether preoperative serum iron status was associated with prognosis after CRC resection.
METHODS METHODS
We evaluated preoperative iron and transferrin saturation (TSAT), which was calculated as iron divided by total iron-binding capacity, in 327 patients who underwent surgery for Stage II-III CRC. Fe < 60 μg/dl and TSAT > 40% were defined as low and high iron, respectively. The associations between iron status and overall survival (OS) were evaluated in univariate and multivariate Cox proportional hazards analysis.
RESULTS RESULTS
Of the 327 patients, 179 (54.7%), 124 (37.9%) and 24 (7.3%) had low, normal and high iron, respectively. In univariate analysis, low iron was associated with shorter OS (hazard ratio [HR] 2.821, 95% confidence interval [CI] 1.451-5.485, P = 0.002). High iron was also associated with shorter OS (HR 3.396, 95% CI 1.359-8.489, P = 0.009). In multivariate analysis, high age (P = 0.002), depth of invasion pT4 (P = 0.012), lymph-node metastasis presence (P = 0.035), low albumin (P = 0.011), low iron (HR 2.282, 95% CI 1.163-4.478, P = 0.016) and high iron (HR 3.757, 95% CI 1.486-9.494 P = 0.005) were independently associated with shorter OS. High iron was associated with the amount of intratumoral Fusobacterium nucleatum compared with normal iron.
CONCLUSION CONCLUSIONS
Both low and high preoperative iron in Stage II-III CRC patients were associated with unfavorable OS in univariate and multivariate analyses.

Identifiants

pubmed: 34302234
doi: 10.1007/s10147-021-01995-9
pii: 10.1007/s10147-021-01995-9
doi:

Substances chimiques

Iron E1UOL152H7

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2037-2045

Subventions

Organisme : Grant-in-Aid for Scientific Research
ID : 19K09199

Informations de copyright

© 2021. Japan Society of Clinical Oncology.

Références

Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108
pubmed: 25651787 doi: 10.3322/caac.21262 pmcid: 25651787
Hashiguchi Y, Muro K, Saito Y et al (2020) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol 25:1–42
pubmed: 31203527 doi: 10.1007/s10147-019-01485-z pmcid: 31203527
Acheson AG, Brookes MJ, Spahn DR (2012) Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: a systematic review and meta-analysis. Ann Surg 256:235–244
pubmed: 22791100 doi: 10.1097/SLA.0b013e31825b35d5 pmcid: 22791100
Pang QY, An R, Liu HL (2019) Perioperative transfusion and the prognosis of colorectal cancer surgery: a systematic review and meta-analysis. World J Surg Oncol 17:7
pubmed: 30611274 pmcid: 6321702 doi: 10.1186/s12957-018-1551-y
Hallet J, Hanif A, Callum J et al (2014) The impact of perioperative iron on the use of red blood cell transfusions in gastrointestinal surgery: a systematic review and meta-analysis. Transfus Med Rev 28:205–211
pubmed: 24997001 doi: 10.1016/j.tmrv.2014.05.004 pmcid: 24997001
Torti SV, Torti FM (2013) Iron and cancer: more ore to be mined. Nat Rev Cancer 13:342–355
pubmed: 23594855 pmcid: 4036554 doi: 10.1038/nrc3495
Brissot P, Ropert M, Le Lan C et al (2012) Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochim Biophys Acta 1820:403–410
pubmed: 21855608 doi: 10.1016/j.bbagen.2011.07.014
Yilmaz B, Li H (2018) Gut microbiota and iron: the crucial actors in health and disease. Pharmaceuticals 11:98
pmcid: 6315993 doi: 10.3390/ph11040098
Mima K, Nishihara R, Qian ZR et al (2016) Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut 65:1973–1980
pubmed: 26311717 doi: 10.1136/gutjnl-2015-310101
Yamamura K, Baba Y, Nakagawa S et al (2016) Human microbiome fusobacterium nucleatum in esophageal cancer tissue is associated with prognosis. Clin Cancer Res 22:5574–5581
pubmed: 27769987 doi: 10.1158/1078-0432.CCR-16-1786
Mima K, Ogino S, Nakagawa S et al (2017) The role of intestinal bacteria in the development and progression of gastrointestinal tract neoplasms. Surg Oncol 26:368–376
pubmed: 29113654 pmcid: 5726560 doi: 10.1016/j.suronc.2017.07.011
Mehta RS, Nishihara R, Cao Y et al (2017) Association of dietary patterns with risk of colorectal cancer subtypes classified by fusobacterium nucleatum in tumor tissue. JAMA Oncol 3:921–927
pubmed: 28125762 pmcid: 5502000 doi: 10.1001/jamaoncol.2016.6374
Cross AJ, Ferrucci LM, Risch A et al (2010) A large prospective study of meat consumption and colorectal cancer risk: an investigation of potential mechanisms underlying this association. Cancer Res 70:2406–2414
pubmed: 20215514 pmcid: 2840051 doi: 10.1158/0008-5472.CAN-09-3929
Bastide NM, Chenni F, Audebert M et al (2015) A central role for heme iron in colon carcinogenesis associated with red meat intake. Cancer Res 75:870–879
pubmed: 25592152 doi: 10.1158/0008-5472.CAN-14-2554
Rossi S, Basso M, Strippoli A et al (2017) Are markers of systemic inflammation good prognostic indicators in colorectal cancer? Clin Colorectal Cancer 16:264–274
pubmed: 28412137 doi: 10.1016/j.clcc.2017.03.015
Katayama H, Kurokawa Y, Nakamura K et al (2016) Extended Clavien–Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria. Surg Today 46:668–685
pubmed: 26289837 doi: 10.1007/s00595-015-1236-x
Mima K, Sakamoto Y, Kosumi K et al (2020) Mucosal cancer-associated microbes and anastomotic leakage after resection of colorectal carcinoma. Surg Oncol 32:63–68
pubmed: 31765952 doi: 10.1016/j.suronc.2019.11.005
McShane LM, Altman DG, Sauerbrei W et al (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93:387–391
pubmed: 16106245 pmcid: 2361579 doi: 10.1038/sj.bjc.6602678
Wu HL, Tai YH, Lin SP et al (2018) The impact of blood transfusion on recurrence and mortality following colorectal cancer resection: a propensity score analysis of 4,030 patients. Sci Rep 8:13345
pubmed: 30190571 pmcid: 6127303 doi: 10.1038/s41598-018-31662-5
Miyamoto Y, Hiyoshi Y, Tokunaga R et al (2020) Postoperative complications are associated with poor survival outcome after curative resection for colorectal cancer: a propensity-score analysis. J Surg Oncol. https://doi.org/10.1002/jso.25961
doi: 10.1002/jso.25961 pubmed: 32346880 pmcid: 32346880
Wilson MJ, van Haaren M, Harlaar JJ et al (2017) Long-term prognostic value of preoperative anemia in patients with colorectal cancer: a systematic review and meta-analysis. Surg Oncol 26:96–104
pubmed: 28317592 doi: 10.1016/j.suronc.2017.01.005 pmcid: 28317592
Braga M, Gianotti L, Vignali A et al (1995) Evaluation of recombinant human erythropoietin to facilitate autologous blood donation before surgery in anaemic patients with cancer of the gastrointestinal tract. Br J Surg 82:1637–1640
pubmed: 8548226 doi: 10.1002/bjs.1800821216
Levine EA, Laborde C, Hambrick E et al (1999) Influence of erythropoietin on transfusion requirements in patients receiving preoperative chemoradiotherapy for rectal cancer. Dis Colon Rectum 42:1065–1069 (discussion 1069–1071)
pubmed: 10458132 doi: 10.1007/BF02236704
Christodoulakis M, Tsiftsis DD (2005) Preoperative epoetin alfa in colorectal surgery: a randomized, controlled study. Ann Surg Oncol 12:718–725
pubmed: 16052276 doi: 10.1245/ASO.2005.06.031
Bohlius J, Schmidlin K, Brillant C et al (2009) Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373:1532–1542
pubmed: 19410717 doi: 10.1016/S0140-6736(09)60502-X
Pascual M, Bohle B, Alonso S et al (2013) Preoperative administration of erythropoietin stimulates tumor recurrence after surgical excision of colon cancer in mice by a vascular endothelial growth factor-independent mechanism. J Surg Res 183:270–277
pubmed: 23348072 doi: 10.1016/j.jss.2012.12.041
Lidder PG, Sanders G, Whitehead E et al (2007) Pre-operative oral iron supplementation reduces blood transfusion in colorectal surgery—a prospective, randomised, controlled trial. Ann R Coll Surg Engl 89:418–421
pubmed: 17535624 pmcid: 1963583 doi: 10.1308/003588407X183364
Keeler BD, Simpson JA, Ng S et al (2014) The feasibility and clinical efficacy of intravenous iron administration for preoperative anaemia in patients with colorectal cancer. Colorectal Dis 16:794–800
pubmed: 24916374 doi: 10.1111/codi.12683
Quinn M, Drummond RJ, Ross F et al (2010) Short course pre-operative ferrous sulphate supplementation–is it worthwhile in patients with colorectal cancer? Ann R Coll Surg Engl 92:569–572
pubmed: 20573311 pmcid: 3229346 doi: 10.1308/003588410X12699663904277
Kam PM, Chu CW, Chan EM et al (2020) Use of intravenous iron therapy in colorectal cancer patient with iron deficiency anemia: a propensity-score matched study. Int J Colorectal Dis 35:521–527
pubmed: 31930457 doi: 10.1007/s00384-020-03508-y pmcid: 31930457
Laso-Morales MJ, Vives R, Gomez-Ramirez S et al (2018) Intravenous iron administration for post-operative anaemia management after colorectal cancer surgery in clinical practice: a single-centre, retrospective study. Blood Transfus 16:338–342
pubmed: 29517968 pmcid: 6034767
Wilson MJ, Dekker JWT, Buettner S et al (2018) The effect of intravenous iron therapy on long-term survival in anaemic colorectal cancer patients: results from a matched cohort study. Surg Oncol 27:192–199
pubmed: 29937171 doi: 10.1016/j.suronc.2018.03.005 pmcid: 29937171
Padmanabhan H, Brookes MJ, Iqbal T (2015) Iron and colorectal cancer: evidence from in vitro and animal studies. Nutr Rev 73:308–317
pubmed: 26011904 doi: 10.1093/nutrit/nuu015
Brookes MJ, Boult J, Roberts K et al (2008) A role for iron in Wnt signalling. Oncogene 27:966–975
pubmed: 17700530 doi: 10.1038/sj.onc.1210711
Chen Y, Fan Z, Yang Y et al (2019) Iron metabolism and its contribution to cancer (Review). Int J Oncol 54:1143–1154
pubmed: 30968149
Kucharzewski M, Braziewicz J, Majewska U et al (2003) Iron concentrations in intestinal cancer tissue and in colon and rectum polyps. Biol Trace Elem Res 95:19–28
pubmed: 14555796 doi: 10.1385/BTER:95:1:19
Cross AJ, Sinha R, Wood RJ et al (2011) Iron homeostasis and distal colorectal adenoma risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Prev Res 4:1465–1475
doi: 10.1158/1940-6207.CAPR-11-0103
Chua AC, Knuiman MW, Trinder D et al (2016) Higher concentrations of serum iron and transferrin saturation but not serum ferritin are associated with cancer outcomes. Am J Clin Nutr 104:736–742
pubmed: 27488234 doi: 10.3945/ajcn.115.129411
Bastide NM, Pierre FH, Corpet DE (2011) Heme iron from meat and risk of colorectal cancer: a meta-analysis and a review of the mechanisms involved. Cancer Prev Res 4:177–184
doi: 10.1158/1940-6207.CAPR-10-0113
Boyer E, Le Gall-David S, Martin B et al (2018) Increased transferrin saturation is associated with subgingival microbiota dysbiosis and severe periodontitis in genetic haemochromatosis. Sci Rep 8:15532
pubmed: 30341355 pmcid: 6195524 doi: 10.1038/s41598-018-33813-0
Loreal O, Gosriwatana I, Guyader D et al (2000) Determination of non-transferrin-bound iron in genetic hemochromatosis using a new HPLC-based method. J Hepatol 32:727–733
pubmed: 10845658 doi: 10.1016/S0168-8278(00)80240-8 pmcid: 10845658
Kozu T, Iinuma G, Ohashi Y et al (2009) Effect of orally administered bovine lactoferrin on the growth of adenomatous colorectal polyps in a randomized, placebo-controlled clinical trial. Cancer Prev Res 2:975–983
doi: 10.1158/1940-6207.CAPR-08-0208
Morita Y, Ishikawa K, Nakano M et al (2017) Effects of lactoferrin and lactoperoxidase-containing food on the oral hygiene status of older individuals: a randomized, double blinded, placebo-controlled clinical trial. Geriatr Gerontol Int 17:714–721
pubmed: 27150460 doi: 10.1111/ggi.12776 pmcid: 27150460

Auteurs

Hiroshi Sawayama (H)

Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan.

Yuji Miyamoto (Y)

Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan.

Kosuke Mima (K)

Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan.

Rikako Kato (R)

Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan.

Katsuhiro Ogawa (K)

Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan.

Yukiharu Hiyoshi (Y)

Department of Gastroenterological Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo, 135-8550, Japan.

Mototsugu Shimokawa (M)

Department of Biostatistics, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan.

Takahiko Akiyama (T)

Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan.

Yuki Kiyozumi (Y)

Department of Biostatistics, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan.

Shiro Iwagami (S)

Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan.

Masaaki Iwatsuki (M)

Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan.

Yoshifumi Baba (Y)

Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan.

Naoya Yoshida (N)

Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan.

Hideo Baba (H)

Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan. hdobaba@kumamoto-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH